COVID-19 Phobia in Patients With Bronchiectasis During Covid-19 Pandemic
COVID-19 Phobia and Quality of Life in Patients With Bronchiectasis During Covid-19 Pandemic
1 other identifier
observational
74
1 country
1
Brief Summary
In the literature, there are no studies evaluating COVID-19 phobia, quality of life, health anxiety, physical activity level and quality of sleep in patients with bronchiectasis during COVID-19 pandemic. The investigators will evaluate these parameters in patients with bronchiectasis and compare the findings of healthy individuals during COVID-19 pandemic
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 23, 2020
CompletedStudy Start
First participant enrolled
July 23, 2020
CompletedFirst Posted
Study publicly available on registry
July 27, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 18, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
January 31, 2021
CompletedMay 13, 2021
December 1, 2020
5 months
July 23, 2020
May 12, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
COVID-19 Phobia
COVID-19 phobia was evaluated with COVID-19 Phobia Scale (C19P-S) and total score ranges from 20-100. Lower scores mean better outcome.
5 minutes
Qol
Quality of life was evaluated with Nottingham Health Profile
10 minutes
Secondary Outcomes (3)
Health anxiety
10 minutes
Physical activity
5 minutes
Quality of sleep
10 minutes
Study Arms (2)
Bronchiectasis
Having been diagnosed with non-cystic fibrosis bronchiectasis
Healthy individuals
Healthy individuals without chronic disease
Eligibility Criteria
Patients and healthy individuals between 18-60 years old, who are diagnosed with non-cystic fibrosis bronchiectasis, and whose local language is Turkish will be included in the study.
You may qualify if:
- Having been diagnosed with non-cystic fibrosis bronchiectasis
- No acute bronchiectasis exacerbation or infection in the past 2 weeks
- Volunteering to participate in the research
You may not qualify if:
- Having a cognitive problem
- Not being literate
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hacettepe University, Faculty of Physical Therapy and Rehabilitation
Ankara, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Merve Firat, MSc
Hacettepe University
- STUDY DIRECTOR
Naciye Vardar-Yagli, PhD
Hacettepe University
- STUDY CHAIR
Deniz İnal-İnce, Professor
Hacettepe University
- STUDY CHAIR
Melda Saglam, PhD
Hacettepe University
- STUDY CHAIR
Ebru Calik-Kütükcü, PhD
Hacettepe University
- STUDY CHAIR
Aslıhan Cakmak, MSc
Hacettepe University
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
July 23, 2020
First Posted
July 27, 2020
Study Start
July 23, 2020
Primary Completion
December 18, 2020
Study Completion
January 31, 2021
Last Updated
May 13, 2021
Record last verified: 2020-12